Factor Xa Derivative Antidote for Reversing Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anticoagulant therapies, particularly those targeting factor Xa inhibitors, face challenges in effectively reversing anticoagulation and managing bleeding risks due to the limitations of available antidotes, such as recombinant factor VIIa, which have mechanistic limitations and potential thrombosis risks.
Innovation Solution
The use of modified factor Xa protein derivatives with reduced or no intrinsic procoagulant activity, capable of binding and neutralizing factor Xa inhibitors, in combination with blood coagulating agents or heparin antidotes, to achieve synergistic or additive effects, allowing for subtherapeutic doses and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If recombinant factor VIIa is used to reverse factor Xa inhibitor activity, then coagulation is restored, but thrombosis risk increases and efficacy is limited by plasma fX concentration
Solution Approach 1:
The patent extracts only the inhibitor-binding capability from factor Xa while removing its procoagulant catalytic function through mutations. This creates a decoy molecule that binds fXa inhibitors without generating thrombin or causing thrombosis, thereby resolving the contradiction between antidote efficacy and thrombosis risk
Solution Approach 2:
The mutated factor Xa derivative serves as an intermediary that mediates between the fXa inhibitor and the coagulation system. It binds the inhibitor to neutralize it, while its mutated form prevents it from acting as a procoagulant, thus resolving the contradiction by introducing a mediating substance with selective functionality
2Reliability
If high concentrations of fXa are used to neutralize fXa inhibitors, then anticoagulation is reversed, but procoagulant activity becomes uncontrolled
Solution Approach 1:
The patent extracts the inhibitor-binding function from factor Xa while removing its procoagulant catalytic activity through site-directed mutations. This creates a molecule that can bind and neutralize fXa inhibitors at high concentrations without generating uncontrolled procoagulant activity
Solution Approach 2:
The patent applies local quality changes by introducing specific mutations at the catalytic site of factor Xa while preserving the inhibitor-binding region. This creates a molecule with non-uniform properties: high affinity for inhibitors but low or no procoagulant activity, thereby resolving the contradiction between neutralization efficacy and procoagulant control
3Reliability
If rfVIIa is used to generate fXa to neutralize inhibitors, then hemostasis is restored, but the amount of fXa produced is limited by circulating plasma fX concentration
Solution Approach 1:
The patent creates a copy of factor Xa's inhibitor-binding capability without its procoagulant function. This mutated derivative can directly bind and neutralize fXa inhibitors without requiring conversion from fX, thereby bypassing the limitation of circulating plasma fX concentration and enabling sufficient neutralization capacity
4Reliability
If factor Xa derivatives with procoagulant activity are used as antidotes, then bleeding is reversed, but risk of undesired thrombosis increases
Solution Approach 1:
The patent extracts the therapeutic antidote function (inhibitor binding) from factor Xa while removing the harmful procoagulant property through mutations. The resulting derivative can reverse bleeding by neutralizing inhibitors without causing undesired thrombosis, as it lacks the catalytic activity to generate excessive clotting
Solution Approach 2:
The patent inverts the normal function of factor Xa by creating a derivative that binds inhibitors but does not promote coagulation. Instead of using active fXa to reverse anticoagulation (which causes thrombosis), the mutated derivative neutralizes the inhibitor without procoagulant effect, thereby resolving the contradiction through functional inversion
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively neutralizes the anticoagulant activity of factor Xa inhibitors, reduces bleeding risks, and initiates coagulation without causing undesired thrombosis, as demonstrated by the ability to reverse anticoagulation and restore hemostasis in clinical scenarios.
Implementation Method 1
The fXa derivative has reduced or no intrinsic procoagulant activity, is capable of binding and/or neutralizing fXa inhibitors
Implementation Method 2
The blood coagulating agent has procoagulant, anti-thrombolytic, and/or anti-fibrinolytic activity
Data Source
AI summary
The present invention relates to antidotes of anticoagulants targeting factor Xa which antidotes are used in combination with blood coagulating agents or other heparin antidotes to prevent or reduce bleeding in a subject. The antidotes described herein have reduced or no intrinsic coagulant activity. Disclosed herein are methods of stopping or preventing bleeding in a patient that is or will be undergoing anticoagulant therapy with a factor Xa inhibitor.